Format

Send to

Choose Destination
Biochim Biophys Acta Mol Basis Dis. 2018 Jun;1864(6 Pt A):2143-2153. doi: 10.1016/j.bbadis.2018.03.023. Epub 2018 Mar 28.

Identification of prion protein-derived peptides of potential use in Alzheimer's disease therapy.

Author information

1
Department of Biochemistry, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Str., 02-093 Warsaw, Poland.
2
Department of Physiology and Biophysics, Case Western Reserve University, Cleveland, OH 44106, USA.
3
Laboratory of Molecular Neurobiology, Centre of New Technologies, University of Warsaw, 02-097 Warsaw, Poland.
4
Department of Biochemistry, Nencki Institute of Experimental Biology of Polish Academy of Sciences, 3 Pasteur Str., 02-093 Warsaw, Poland. Electronic address: k.nieznanski@nencki.gov.pl.

Abstract

Soluble form of the prion protein (PrP) has been previously shown to interact with amyloid-β (Aβ) peptides, suppressing their fibrillization as well as toxicity, which indicates that this protein may play a protective role in Alzheimer's disease (AD). The shortest known PrP fragment retaining all of these properties corresponds to physiologically generated proteolytic polypeptide PrP23-110/111, called N1. Here we have identified two N1-derived synthetic peptides, encompassing residues 23-50 (PrP23-50) and 90-112 (PrP90-112), which bind to Aβ1-42 protofibrillar oligomers as well as amyloid fibrils. We found that, akin to N1, the abovementioned synthetic peptides not only reduce the initial rate of Aβ fibrillization, but also alter the aggregation pathway of Aβ, inhibiting formation of protofibrillar oligomers and facilitating amorphous aggregation. Furthermore, our data show that N1, PrP23-50 and PrP90-112 protect cultured hippocampal neurons from neurotoxic effects of Aβ oligomers, preventing oligomers-induced retraction of neurites and loss of cell membrane integrity. The above PrP fragments can also attenuate neuronal intake of Aβ. Our results strongly suggest that synthetic peptides such as PrP23-50 and PrP90-112 can be useful in designing a novel class of therapeutics in AD.

KEYWORDS:

Alzheimer's disease; Amyloid; Aβ peptide; Neurotoxicity; Prion protein

PMID:
29604335
DOI:
10.1016/j.bbadis.2018.03.023
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center